Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008

OBJECTIVE: Infants with chronic lung disease of infancy (CLDI) are at high risk for severe respiratory syncytial virus (RSV) illness requiring hospitalization. Palivizumab was first licensed in 1998 for the prevention of RSV disease in high-risk infants, including those with CLDI. We performed a ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Groothuis, Jessie R, Fryzek, Jon P, Makari, Doris, Steffey, Duane, Martone, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191114/
https://www.ncbi.nlm.nih.gov/pubmed/22003308
http://dx.doi.org/10.2147/CLEP.S17189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191114/
https://www.ncbi.nlm.nih.gov/pubmed/22003308
http://dx.doi.org/10.2147/CLEP.S17189

Ejemplares similares